vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and PATHWARD FINANCIAL, INC. (CASH). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($276.3M vs $154.2M, roughly 1.8× BridgeBio Pharma, Inc.). PATHWARD FINANCIAL, INC. runs the higher net margin — 26.4% vs -126.2%, a 152.6% gap on every dollar of revenue.
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
BBIO vs CASH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $276.3M |
| Net Profit | $-194.6M | $72.9M |
| Gross Margin | 94.7% | — |
| Operating Margin | -90.5% | — |
| Net Margin | -126.2% | 26.4% |
| Revenue YoY | 2521.2% | — |
| Net Profit YoY | 27.2% | — |
| EPS (diluted) | $-1.00 | $3.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $276.3M | ||
| Q4 25 | $154.2M | $173.1M | ||
| Q3 25 | $120.7M | $186.7M | ||
| Q2 25 | $110.6M | $195.8M | ||
| Q1 25 | $116.6M | $274.8M | ||
| Q4 24 | — | $182.6M | ||
| Q3 24 | — | $179.5M | ||
| Q2 24 | — | $188.6M |
| Q1 26 | — | $72.9M | ||
| Q4 25 | $-194.6M | $35.2M | ||
| Q3 25 | $-184.9M | $38.8M | ||
| Q2 25 | $-183.8M | $42.1M | ||
| Q1 25 | $-169.6M | $75.0M | ||
| Q4 24 | — | $30.0M | ||
| Q3 24 | — | $33.5M | ||
| Q2 24 | — | $44.9M |
| Q1 26 | — | — | ||
| Q4 25 | 94.7% | — | ||
| Q3 25 | 94.6% | — | ||
| Q2 25 | 96.7% | — | ||
| Q1 25 | 97.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -90.5% | 24.6% | ||
| Q3 25 | -120.3% | 25.9% | ||
| Q2 25 | -121.4% | 24.1% | ||
| Q1 25 | -89.5% | 33.2% | ||
| Q4 24 | — | 19.8% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | — | 27.1% |
| Q1 26 | — | 26.4% | ||
| Q4 25 | -126.2% | 20.3% | ||
| Q3 25 | -153.2% | 20.8% | ||
| Q2 25 | -166.2% | 21.5% | ||
| Q1 25 | -145.4% | 27.3% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | 18.7% | ||
| Q2 24 | — | 23.8% |
| Q1 26 | — | $3.35 | ||
| Q4 25 | $-1.00 | $1.57 | ||
| Q3 25 | $-0.95 | $1.69 | ||
| Q2 25 | $-0.95 | $1.81 | ||
| Q1 25 | $-0.88 | $3.14 | ||
| Q4 24 | — | $1.23 | ||
| Q3 24 | — | $1.34 | ||
| Q2 24 | — | $1.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $157.6M |
| Total DebtLower is stronger | $2.0B | $59.5M |
| Stockholders' EquityBook value | $-2.1B | $850.7M |
| Total Assets | $936.0M | $7.1B |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $157.6M | ||
| Q4 25 | $570.1M | $331.2M | ||
| Q3 25 | $643.0M | $120.6M | ||
| Q2 25 | $756.9M | $258.3M | ||
| Q1 25 | $540.6M | $254.2M | ||
| Q4 24 | — | $597.4M | ||
| Q3 24 | — | $158.3M | ||
| Q2 24 | — | $298.9M |
| Q1 26 | — | $59.5M | ||
| Q4 25 | $2.0B | $33.5M | ||
| Q3 25 | $2.0B | $33.5M | ||
| Q2 25 | — | $33.4M | ||
| Q1 25 | — | $33.4M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $33.3M |
| Q1 26 | — | $850.7M | ||
| Q4 25 | $-2.1B | $854.5M | ||
| Q3 25 | $-1.9B | $858.0M | ||
| Q2 25 | $-1.8B | $819.0M | ||
| Q1 25 | $-1.6B | $814.7M | ||
| Q4 24 | — | $758.3M | ||
| Q3 24 | — | $822.5M | ||
| Q2 24 | — | $748.4M |
| Q1 26 | — | $7.1B | ||
| Q4 25 | $936.0M | $7.6B | ||
| Q3 25 | $998.3M | $7.2B | ||
| Q2 25 | $1.1B | $7.2B | ||
| Q1 25 | $881.6M | $7.0B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.5B | ||
| Q2 24 | — | $7.5B |
| Q1 26 | — | 0.07× | ||
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | — |
| Free Cash FlowOCF − Capex | $-56.5M | — |
| FCF MarginFCF / Revenue | -36.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-56.4M | $108.3M | ||
| Q3 25 | $-109.6M | $303.7M | ||
| Q2 25 | $-80.7M | $30.4M | ||
| Q1 25 | $-199.2M | $188.3M | ||
| Q4 24 | — | $-71.7M | ||
| Q3 24 | — | $143.1M | ||
| Q2 24 | — | $113.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-56.5M | $104.1M | ||
| Q3 25 | $-110.0M | $300.3M | ||
| Q2 25 | $-81.3M | $27.7M | ||
| Q1 25 | — | $184.7M | ||
| Q4 24 | — | $-73.8M | ||
| Q3 24 | — | $138.8M | ||
| Q2 24 | — | $111.0M |
| Q1 26 | — | — | ||
| Q4 25 | -36.6% | 60.1% | ||
| Q3 25 | -91.2% | 160.9% | ||
| Q2 25 | -73.5% | 14.1% | ||
| Q1 25 | — | 67.2% | ||
| Q4 24 | — | -40.4% | ||
| Q3 24 | — | 77.3% | ||
| Q2 24 | — | 58.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.4% | 1.8% | ||
| Q2 25 | 0.5% | 1.4% | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 1.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.08× | ||
| Q3 25 | — | 7.83× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 2.51× | ||
| Q4 24 | — | -2.39× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 2.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
